Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
Immunovant director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction. On the same day, he exercised options to acquire 1,500 shares of Common Stock at $8.43 per share and sold 1,500 shares in an open-market transaction at $34.02 per share.
The filing shows he continues to hold 116,731 Common Stock shares directly and 20,000 shares indirectly through a trust, as well as 69,681 remaining stock options after the exercise. The transactions were carried out under a Rule 10b5-1 trading plan adopted on December 26, 2025, indicating they were pre-scheduled rather than discretionary.
Issuer files a Form 144 reporting proposed sale and recent dispositions of Common Stock. The filing lists 6,000 shares tied to an exercise of stock options with a proposed sale date of 06/15/2026. It also reports prior 10b5-1 sales of 6,000 shares on 05/20/2026 for $192,000.
Immunovant, Inc. director Andrew J. Fromkin reported a combination of option exercises and share sales in common stock. On May 28, 2026, he exercised stock options covering 196,601 shares at strike prices ranging from $4.99 to $14.70 per share, converting derivative awards into common shares.
On the same date, he executed open-market sales totaling 221,951 shares of common stock at weighted average prices of $33.56 and $32.64 per share across multiple trades. Following these transactions, he directly holds 74,382 Immunovant common shares, indicating a net reduction in his direct equity position while retaining a meaningful stake.
IMVT (reported by Morgan Stanley Smith Barney LLC Executive Financial Services) filed Form 144 reporting proposed sales of Common shares. The notice lists multiple proposed sale methods and dates, including exercise of options under a registered plan, restricted stock vesting, and an open market purchase.
The filing itemizes individual lot sizes on specific dates, including 16,260, 49,961, 77,181, and other share amounts; these are presented as proposed dispositions rather than aggregated totals.
Immunovant, Inc.’s Chief Operating Officer, Gloria Melanie, reported selling a total of 3,115 shares of common stock on May 20, 2026 in open-market transactions at prices including $30.41, $32.15, and $32.95 per share. A footnote explains these sales were executed solely to cover tax withholding obligations arising from the vesting and settlement of 6,872 restricted stock units granted as part of a larger 109,956 RSU award from November 18, 2024. The issuance’s “sell to cover” structure was chosen by the company and described as a mandated, non-discretionary transaction by the executive. The Form 4 data also reflect a reported direct holding of 244,973 shares of Immunovant common stock after the transactions.
Immunovant, Inc. director Atul Pande reported an option exercise and share sale. On May 20, 2026, he exercised stock options to acquire 6,000 shares of common stock at $8.43 per share and sold 6,000 shares at $32.00 per share.
After these transactions, he directly holds 116,731 common shares and indirectly holds 20,000 shares through a trust. A related footnote states the sale occurred under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was planned in advance.
Immunovant, Inc. is a clinical-stage immunology company focused on IMVT-1402 (imeroprubart), a fully human anti‑FcRn antibody intended to treat IgG‑mediated autoimmune diseases across endocrinology, neurology, rheumatology and dermatology.
Phase 1 data in healthy adults showed deep, dose‑dependent IgG reductions, supporting a potential best‑in‑class profile with subcutaneous self‑administration via an autoinjector. The company has ongoing studies in six indications, including potentially registrational trials in Graves’ disease, difficult‑to‑treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease, plus a proof‑of‑concept trial in cutaneous lupus erythematosus.
In April 2026, top‑line Phase 3 results for its first‑generation antibody batoclimab in thyroid eye disease failed to meet the primary endpoint, and Immunovant decided to discontinue batoclimab development to concentrate resources on IMVT‑1402 while leveraging prior clinical and operational learnings.
Immunovant, Inc. reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026. Lead asset IMVT-1402 showed encouraging preliminary results in difficult-to-treat rheumatoid arthritis, with Week 16 ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8% in the open-label period. A proof-of-concept trial in cutaneous lupus erythematosus is fully enrolled, and potentially registrational studies in Graves’ disease, myasthenia gravis, CIDP and Sjögren’s disease remain on track, with multiple topline readouts expected in 2026–2027. The company discontinued batoclimab after two Phase 3 thyroid eye disease trials did not meet their primary endpoint and is redirecting resources to IMVT-1402.
For the quarter, research and development expenses were $142.3 million and net loss was $147.9 million, or $0.73 per share. For the full fiscal year, research and development expenses were $456.7 million and net loss was $505.6 million, or $2.77 per share. Cash and cash equivalents totaled $902.1 million as of March 31, 2026, which management states provide runway through the potential commercial launch of IMVT-1402 in Graves’ disease.
Immunovant, Inc. director Robert Graham Susman reported an open-market sale of 2,502 shares of common stock at a weighted average price of $27.17 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 30, 2025.
Following this sale, he directly holds 36,394 shares of Immunovant common stock, so the filing reflects a partial reduction rather than an exit from his position.